methyl-(β-hydroxy-isopentyl)-amine | 42163-28-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: methyl-(β-hydroxy-isopentyl)-amine
• 英文别名: 3-methyl-1-(methylamino)butan-2-ol
• CAS: 42163-28-0
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: RAKKFSLKTUFWPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]-pyridine-5-carboxamide 、 methyl-(β-hydroxy-isopentyl)-amine 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-chlorobenzyl)-2-(((2-hydroxy-3-methylbutyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
  参考文献：
  名称：

  2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases

  摘要：

  A novel series of 2-aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides have been identified as potent antivirals against human herpesviruses. These compounds demonstrate broad-spectrum inhibition of the herpesvirus polymerases HCMV, HSV-1, EBV, and VZV with high specificity compared to human DNA polymerases. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.102
• 作为产物：
  描述：

  1,2-环氧-3-甲基丁烷 、 甲胺 在 水 作用下， 生成 methyl-(β-hydroxy-isopentyl)-amine
  参考文献：
  名称：

  Uschenko, Chemical Abstracts, 1943, p. 4396

  摘要：

  DOI：

文献信息

• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2020186199A1

  公开（公告）日：2020-09-17

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。
• Carboxamide Derivatives and Use Thereof
  申请人：PURDUE PHARMA L.P.

  公开号：US20160031873A1

  公开（公告）日：2016-02-04

  The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: R 10 Z-HET-E I-A and the pharmaceutically acceptable salts and solvates thereof, wherein Z, HET, R 10 and E are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I-A to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供了公式I-A的取代吡啶基、嘧啶基、吡嗪基、吡啉基和三嗪基羧酰胺，以及其药学上可接受的盐和溶剂化合物，其中Z、HET、R10和E如规范中所定义。本公开还涉及使用公式I-A的化合物治疗对钠通道阻滞有响应的疾病。本公开的化合物特别适用于治疗疼痛。
• Hiv Integrase Inhibitors
  申请人：Wai S. John

  公开号：US20080015187A1

  公开（公告）日：2008-01-17

  Bicyclic pyrazoles of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein Z is O or N(R 8 ); n is an integer equal to zero or 1; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  式I中的双环吡唑是HIV整合酶的抑制剂和HIV复制的抑制剂：其中Z是O或N（R8）; n是等于零或1的整数; R1、R2、R3、R4、R5、R6、R7和R8在此定义。这些化合物对预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病非常有用。这些化合物可作为化合物本身或以药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为药物组成部分，可与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Carboxamide derivatives and use thereof
  申请人：Purdue Pharma L.P.

  公开号：US10005768B2

  公开（公告）日：2018-06-26

  The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein Z, HET, R10, and E are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I-A to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供了式 I-A 的取代吡啶基、嘧啶基、吡嗪基、哒嗪基和三嗪基羧酰胺： 及其药学上可接受的盐和溶液，其中 Z、HET、R10 和 E 的定义如说明书所述。本公开还涉及使用式 I-A 的化合物治疗对钠离子通道阻断有反应的疾病。本公开的化合物尤其适用于治疗疼痛。
• Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors
  作者：H. Marie Langford、Peter D. Williams、Carl F. Homnick、Joseph P. Vacca、Peter J. Felock、Kara A. Stillmock、Marc V. Witmer、Daria J. Hazuda、Lori J. Gabryelski、William A. Schleif

  DOI：10.1016/j.bmcl.2007.11.049

  日期：2008.1

  A series of 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides was synthesized and tested for their inhibition of HIV-1 integrase catalytic activity and HIV-1 replication in cells. Structure-activity studies around lead compound 5 indicated that a coplanar relationship of metal-binding heteroatoms provides optimal binding to the integrase active site. Identification of potency-enhancing substituents and adjustments in lipophilicity provided 17b which inhibits integrase-catalyzed strand transfer with an IC50 value of 74 nM and inhibits HIV-1 replication in cell culture in the presence of 50% normal human serum with an IC95 value of 63 nM. (c) 2007 Elsevier Ltd. All rights reserved.